scholarly journals Preparation and antitumor evaluation of self-assembling oleanolic acid-loaded Pluronic P105/D-α-tocopheryl polyethylene glycol succinate mixed micelles for non-small-cell lung cancer treatment

2016 ◽  
Vol Volume 11 ◽  
pp. 6337-6352 ◽  
Author(s):  
Hao Wu ◽  
Qingxiang Zhong ◽  
Rongling Zhong ◽  
Houcai Huang ◽  
Zhi Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polyethylene Glycol ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Mixed Micelles ◽  
Small Cell ◽  
Glycol Succinate ◽  
Small Cell Lung ◽  
Self Assembling ◽  
Antitumor Evaluation

Small cell lung cancer treatment in Paul Stradins Clinical University Hospital (Riga, Latvia) – Update after 3 year follow up

Lung Cancer ◽  
2012 ◽  
Vol 77 ◽  
pp. S34-S35
Author(s):  
Viktors Kozirovskis ◽  
Vija Bērziņa ◽  
Aija Geriņa-Bērziņa ◽  
Elīna Skuja ◽  
Arturs Šorubalko ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
University Hospital ◽  
Small Cell Lung ◽  
Lung Cancer Treatment

Outcomes of Proton Therapy for Non-small Cell Lung Cancer in Patients with Interstitial Pneumonia

2021 ◽  
Author(s):  
Shingo Hashimoto ◽  
Hiromitsu Iwata ◽  
Yukiko Hattori ◽  
Koichiro Nakajima ◽  
Kento Nomura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Interstitial Pneumonia ◽  
Proton Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Grade 3

Abstract Background:Interstitial pneumonia (IP) is a disease with a poor prognosis. In addition, IP patients are more likely to develop lung cancer. Since IP patients frequently develop toxicities during cancer treatment, minimally invasive cancer treatment is warranted for such patients to maintain their quality of life. This study retrospectively investigated the efficacy and safety of proton therapy (PT) for non-small cell lung cancer (NSCLC) in patients with IP.Methods:Twenty-nine NSCLC patients with IP were treated with PT between September 2013 and December 2019. The patients had stage IA to IIIB primary NSCLC. Ten of the 29 patients exhibited the usual interstitial pneumonia pattern. The prescribed dose was 66-74 Grays (relative biological effectiveness) in 10-37 fractions.Results:The median follow-up period was 17.4 months (interquartile range (IQR), 9.5–32.7). The median patient age was 77 years (IQR, 71–81). The median planning target volume was 112.0 ml (IQR, 56.1–246.3). The 2-year local control, progression-free survival, and overall survival rates were 77% (95% confidence interval: 34 to 94), 31% (13–50), and 50% (26–70), respectively. According to the Common Terminology Criteria for Adverse Events (version 4.0), grade 3 acute radiation pneumonitis (RP) was observed in 1 patient. Two patients developed grade 3 late RP, but no other patients experienced serious toxicities. The patients’ quality of life (European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 and SF-36) scores had not changed after 3 months.Conclusions:PT may safely control NSCLC without adversely affecting the daily lives of IP patients.

Immune checkpoint inhibitors: Significant advancements in non–small cell lung cancer treatment

2021 ◽  
Author(s):  
Ashley E Glode ◽  
Megan B May
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Novel Therapies ◽  
Small Cell Lung

Abstract Purpose This article explores the efficacy, toxicity, place in therapy, and considerations for use of recently approved immune checkpoint inhibitors (ICIs) in the treatment of non–small cell lung cancer (NSCLC). Summary Lung cancer is the leading cause of cancer mortality in the United States and is responsible for more cancer-related deaths than breast, prostate, and colorectal cancer combined. The landscape for lung cancer treatment is evolving with the approval of new and exciting novel therapies. Within the last decade numerous ICIs have been approved for use in the management of the most common subtype of lung cancer, NSCLC. The ICI agents currently approved by the Food and Drug Administration (FDA) for use in NSCLC include ipilimumab, pembrolizumab, nivolumab, durvalumab, and atezolizumab. These agents are approved for specific indications; therefore, they are not interchangeable. This review focuses on the landmark trials that led to each FDA-approved indication, as well as common toxicities seen with use of these agents. It also discusses the use of ICIs in special populations and unique considerations prior to initiation of treatment with these novel therapies in a patient with NSCLC. Conclusion ICIs can provide a breakthrough treatment option for the management of NSCLC and are rapidly being adopted into clinical practice. It is important to be familiar with appropriate selection of an ICI therapy option for each patient based on approved indication, unique considerations, and anticipated toxicities.

scholarly journals Immunotherapy for non-small cell lung cancer treatment

2016 ◽  
pp. 17-24 ◽  
Author(s):  
K. K. LAKTIONOV ◽  
K. A. SARANTSEVA ◽  
V. V. BREDER ◽  
M. A. OKRUZHNOVA ◽  
M. V. PEREGUDOVA
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Treatment
Sign in / Sign up

Export Citation Format

Share Document